2.1.2.3	-	485757, 485758	
2.1.2.3	ATIC complex crystallized in monoclinic space group P2(1), a = 56.48 A, b = 107.88 A, c = 103.86 A and beta = 91.2°	485746, 485755, 485759, 485760	
2.1.2.3	crystal structure analysis of human enzyme complexed with the sulfamido-bridged N-[(S)-(4-([(2-amino-4-hydroxy-quinazolin-6-yl)dihydroxy-lambda-4-sulfanyl]amino)phenyl)-hydroxymethyl]-L-glutamic acid at 2.55 A resolution, PDB ID 1P4R	736619	
2.1.2.3	crystallized in a binary complex with methotrexate, single crystal at 96 K to 2.3 A resolution, monoclinic crystals, space group P2(1), with unit-cell dimensions a = 65.17, B = 105.93, c= 103.47 A, beta = 108.27 degrees	485755	
2.1.2.3	crystallized in complex with its inhibitor 2-[5-hydroxy-3-methyl-1-(2-methyl-4-sulfophenyl)-1H-pyrazo]-4-sulfobenzoic acid	659419	
2.1.2.3	purified recombinant His-tagged enzyme free or in complex with substrate 5-aminoimidazole-4-carboxamide ribonucleotide, both with adventitiously active site-bound nucleotide inhibitor of the cyclohydrolase activity, X-ray diffraction structure determination and analysis at 2.5 A and 2.2 A resolution, respectively	719985	
2.1.2.3	purified recombinant His6-tagged PurH, without methylation of the 28 lysine residues, sitting drop vapour diffusion method, mixing of 0.001 ml of 56 mg/ml protein in 0.8 M sodium/potassium hydrogen phosphate, pH 7.5, with 0.001 ml of reservoir solution containing 0.1 M sodium acetate, pH 5.0, 1 M ammonium sulfate, 1 week to 1 month, X-ray diffraction structure determination and analysis at 3.05 A resolution	718506	
2.1.2.3	recombinant His-tag fusion protein crystallized by sitting drop vapor diffusion method in complex with its inhibitor beta-DADF	657946	
2.1.2.3	sitting drop vapor diffusion method, co-crystallized in the presence of substrate with BW1540 and BW2315	652530	
2.1.2.3	the three-dimensional structure of TM1249 is determined to 1.88 A resolution by molecular replacement	689976